JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo(Kindai University), Osamu Matsui(Kanazawa University), Namiki Izumi(Musashino Red Cross Hospital), Hiroko Iijima(Hyogo Medical University), Masumi Kadoya(Shinshu University), Yasuharu Imai(Ikeda Municipal Hospital), Takuji Okusaka, Shiro Miyayama(Fukui-ken Saiseikai Hospital), Kaoru Tsuchiya(Musashino Red Cross Hospital), Kazuomi Ueshima(Kindai University), Atsushi Hiraoka(Ehime Prefectural Central Hospital), Masafumi Ikeda(National Cancer Center Hospital East), Sadahisa Ogasawara(Chiba University), Tatsuya Yamashita(Kanazawa University Hospital), Tetsuya Minami(Kanazawa University Hospital), Koichiro Yamakado(Mie University), on behalf of the Liver Cancer Study Group of Japan
Cited by 632Open Access
Abstract
The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan. Three important items have been updated: the surveillance and diagnostic algorithm, the treatment algorithm, and the definition of transarterial chemoembolization (TACE) failure/refractoriness. The most important update to the diagnostic algorithm is the inclusion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a first line surveillance/diagnostic tool. Another significant update concerns removal of the term "lipiodol" from the definition of TACE failure/refractoriness.
Related Papers
Scirrhous Hepatocellular Carcinoma on Gadoxetic Acid–Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging
Min Jung Park, Young Kon Kim, Hyun Jeong Park et al.|Journal of Computer Assisted Tomography|2013|47